Status:
COMPLETED
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, in...
Eligibility Criteria
Inclusion
- Are considered healthy as determined by medical evaluation including medical history and physical examination
- Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive
Exclusion
- Have current or a history of pancreatitis or hepatitis
- Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening
- Have uncontrolled high blood pressure
- Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 26 2025
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT06890611
Start Date
March 25 2025
End Date
September 26 2025
Last Update
October 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247